A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

Study Identifier
M16-904
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Protocol
Available Language(s): English
Statistical Analysis Plan
Available Language(s): English
Plain Language Summary
Available Language(s): English

Study Details

Medical Condition
  • Women's Health & Pregnancy - Other
  • Study Drug
  • Leuprolide Acetate (LA)
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    2 - 11 Years

    Protocol Summary

    The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.

    Study Locations

    Location
    Status
    Location
    Pediatric Endocrinology Associates /ID# 200629
    Long Beach, California, United States, 90806-1651
    Status
    Not applicable
    Location
    Rady Children's Hospital San Diego /ID# 202491
    San Diego, California, United States, 92123
    Status
    Not applicable
    Location
    Children's Hospital Colorado /ID# 201645
    Aurora, Colorado, United States, 80045
    Status
    Not applicable
    Location
    Pediatric Endocrine Associates /ID# 201089
    Greenwood Village, Colorado, United States, 80111
    Status
    Not applicable
    Location
    Nemours Children's Health System /ID# 201331
    Jacksonville, Florida, United States, 32207
    Status
    Not applicable
    Location
    Arnold Palmer Hospital /ID# 201624
    Orlando, Florida, United States, 32806
    Status
    Not applicable
    Showing {first} - {last} of {total} Results